长链非编码RNA TUBA4B与Ⅱ型子宫内膜癌患者预后的关系

Abstract
Figure/Table
References (26)
Related Citation (15)

Download: PDF (777 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the relationship between long noncoding RNA (lncRNA) TUBA4B and prognosis of patients with type Ⅱ endometrial carcinoma (EC). Methods A total of 123 patients with type Ⅱ EC treated in the North China University of Science and Technology Affiliated Hospital from March 2013 to July 2017 were selected as the study subjects. Data on EC differentiation, International Federation of Gynecology and Obste-trics staging (FIGO staging) and treatment of patients were collected. The patients with type Ⅱ EC were divided into survival group (82 cases) and death group (41 cases) according to the three-year prognosis. The level of lncRNA TUBA4B in EC tissues was detected by real-time quantitative PCR. Receiver operator characteristic curve was used to evaluate the diagnostic value of lncRNA TUBA4B for the prognosis of EC. The patients were divided into high TUBA4B group (TUBA4B > 0.70, 93 cases) and low TUBA4B group (TUBA4B≤0.70, 30 cases) according to the optimal cut-off point of prognosis of type Ⅱ EC patients diagnosed. The survival of high TUBA4B group and low TUBA4B group were analyzed, and the risk factors for prognosis of EC were analyzed by Cox regression. The relationship between lncRNA TUBA4B and the prognosis of EC was analyzed by restrictive cubic spline fitting Cox regression. Results The three-year survival rate of type Ⅱ EC patients was 66.67%. The level of lncRNA TUBA4B in survival group was higher than that in death group, and the difference was statistically significant (P ＜ 0.05). The area under the receiver operating characteristic curve, sensitivity and specificity of LncRNA TUBA4B for the prognosis of type Ⅱ EC patients were 0.836, 63.41% and 95.12%, respectively. The median survival time of the high TUBA4B group was higher than that of the low TUBA4B group, and the difference was statistically significant (P ＜ 0.05). Cox multivariate analysis showed that high FIGO stage and complex treatment were independent risk factors for prognosis of type Ⅱ EC (HR = 3.466, 1.751, P ＜ 0.05). High degree of differentiation and high level of lncRNA TUBA4B were independent protective factors for prognosis of type Ⅱ EC (P ＜ 0.05). The results of restrictive cubic spline fitting Cox regression analysis showed that lncRNA TUBA4B was correlated with the prognosis of type Ⅱ EC (P < 0.05), and the relationship was nonlinear (HR = 0.516, 0.073, P ＜ 0.05). Concluson The level of LncRNA TUBA4B is associated with the prognosis of type Ⅱ EC, and a high level of LncRNA TUBA4B indicates a low risk of poor prognosis.

Key words： Type Ⅱ endometrial cancer Long noncoding RNA TUBA4B Prognosis

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	GUO Yanjuan ZHAO Nannan ZHOU Jianli DONG Jianxin YUAN Jinling GAO Jie

Cite this article:

GUO Yanjuan ZHAO Nannan ZHOU Jianli DONG Jianxin YUAN Jinling GAO Jie. Relationship between long noncoding RNA TUBA4B and prognosis of patients with type Ⅱ endometrial carcinoma[J]. 中国医药导报, 2021, 18(27): 12-16.

URL:

https://www.yiyaodaobao.com.cn/EN/ OR https://www.yiyaodaobao.com.cn/EN/Y2021/V18/I27/12

[1] Bray F，Ferlay J，Soerjomataram I，et al. Global cancer statistics 2018：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin，2018，68（6）：394-424.
[2] Siegel RL，Miller KD，Jemal A. Cancer statistics，2020 [J]. CA Cancer J Clin，2020，70（1）：7-30.
[3] 蓝喜，何文雯，郑成军，等.Ⅱ型子宫内膜癌预后因素的COX回归分析[J].昆明医科大学学报，2020，41（7）：160-164.
[4] Fernando TR，Contreras JR，Zampini M，et al. The lncRNA CASC15 regulates SOX4 expression in RUNX1-rearranged acute leukemia [J]. Mol Cancer，2017，16（1）：126.
[5] Shi F，Wang T，Liu Z，et al. LncRNA miR143HG Up-Regulates p53 In Endometrial Carcinoma By Sponging miR-125a [J]. Cancer Manag Res，2019，11：10117-10123.
[6] Wang W，Ge L，Xu XJ，et al. LncRNA NEAT1 promotes endometrial cancer cell proliferation，migration and invasion by regulating the miR-144-3p/EZH2 axis [J]. Radiol Oncol，2019，53（4）：434-442.
[7] Ke J，Shen Z，Hu W，et al. LncRNA DCST1-AS1 Was Upregulated in Endometrial Carcinoma and May Sponge miR-92a-3p to Upregulate Notch1 [J]. Cancer Manag Res，2020，12：1221-1227.
[8] Guo J，Li Y，Duan H，et al. LncRNA TUBA4B functions as a competitive endogenous RNA to inhibit gastric cancer progression by elevating PTEN via sponging miR-214 and miR-216a/b [J]. Cancer Cell Int，2019，19：156.
[9] Wang QA，Yang Y，Liang X. LncRNA CTBP1-AS2 sponges miR-216a to upregulate PTEN and suppress endometrial cancer cell invasion and migration [J]. J Ovarian Res，2020，13（1）：37.
[10] 中国抗癌协会妇科肿瘤专业委员会.子宫内膜癌诊断与治疗指南（第四版）[J].中国实用妇科与产科杂志，2018， 34（8）：880-886.
[11] Su Y，Li Q，Zheng Z，et al. Integrative bioinformatics analysis of miRNA and mRNA expression profiles and identification of associated miRNA-mRNA network in aortic dissection [J]. Medicine（Baltimore），2019，98（24）：e16013.
[12] 王建六，李斌，吴玉梅，等.子宫内膜透明细胞癌的中国专家共识（2020年版）[J].医学综述，2020，26（16）：3121-3129.
[13] 廖茜茜.血清CA125、HE4对Ⅱ型子宫内膜癌术后复发的预测及监控价值[D].重庆：重庆医科大学，2020.
[14] 琚莹，杨君.MicroRNA-182和Ki-67在Ⅰ型和Ⅱ型子宫内膜癌组织中的表达[J].新乡医学院学报，2020，37（1）：57-62.
[15] 张珺，李星，毛林.前哨淋巴结定位在Ⅱ型子宫内膜癌术中应用的研究进展[J].实用妇产科杂志，2020，36（12）：912-915.
[16] 张远丽.不同子宫切除范围对Ⅱ期子宫内膜癌预后的影响[D].济南：山东大学，2020.
[17] Jiang P，Huang J，Deng Y，et al. Predicting Recurrence in Endometrial Cancer Based on a Combination of Classical Parameters and Immunohistochemical Markers [J]. Cancer Manag Res，2020，12：7395-7403.
[18] Li M，Li M，Wei Y，et al. Prognostic and Clinical Significance of Cyclooxygenase-2 Overexpression in Endometrial Cancer：A Meta-Analysis [J]. Front Oncol，2020， 10：1202.
[19] Pique DG，Greally JM，Mar JC. Identification of a novel subgroup of endometrial cancer patients with loss of thyroid hormone receptor beta expression and improved survival [J]. BMC Cancer，2020，20（1）：857.
[20] 乐露露，罗吉，吴海芳，等.子宫内膜癌预后相关差异表达基因筛选及其生物信息学分析[J].山东医药，2020， 60（29）：19-22.
[21] 刘洋，杨秀梅，邵迎华，等.青蒿琥酯对子宫内膜癌细胞凋亡及PARP-1蛋白的影响[J].疑难病杂志，2020，19（11）：1157-1160.
[22] 王雅迪，于风胜，刘海梅，等.特殊类型子宫内膜癌的临床特征及预后分析[J].实用妇产科杂志，2020，36（8）：615-620.
[23] Sideris M，Emin EI，Abdullah Z，et al. The Role of KRAS in Endometrial Cancer：A Mini-Review [J]. Anticancer Res，2019，39（2）：533-539.
[24] Li Y，Li J，Guo E，et al. Integrating pathology，chromosomal instability and mutations for risk stratification in early-stage endometrioid endometrial carcinoma [J]. Cell Biosci，2020，10：122.
[25] Bartosch C，Pires M，Jerónimo C，et al. The role of pathology in the management of patients with endometrial carcinoma [J]. Future Oncol，2017，13（11）：1003-1020.
[26] Huvila J，Pors J，Thompson EF，et al. Endometrial carcinoma：molecular subtypes，precursors and the role of pathology in early diagnosis [J]. J Pathol，2021，253（4）：355-365.